Mark Awadalla

Mark Awadalla's Title

Mark Awadalla currently holds the position of Vice President of Clinical Operations at Capricor, a role he assumed in 2023. In this capacity, he oversees the strategic planning and execution of clinical trials, ensuring that they align with regulatory standards and company objectives. His expertise in clinical operations is pivotal in advancing Capricor's cell therapy programs across various therapeutic areas.

Mark Awadalla's Company

Mark Awadalla joined Capricor, a biotechnology company focused on developing cell and exosome-based therapeutics for the treatment of diseases, in 2023. Capricor is known for its innovative approaches in regenerative medicine and has a strong pipeline of clinical candidates targeting conditions such as Duchenne muscular dystrophy and inflammatory disorders. Awadalla’s role at Capricor is instrumental in driving the company's clinical initiatives forward.

Mark Awadalla's Experience

Before joining Capricor, Mark Awadalla amassed extensive experience in clinical operations and research. He served as Vice President of Research and Development and Head of Clinical Operations at Celularity Inc., where he designed and executed multiple clinical trials. At Mustang Bio, he led the clinical operations team, successfully clearing Investigational New Drug (IND) applications and initiating their first clinical trial with an autologous cell therapy product. His career also includes significant roles at Celgene, where he contributed to the NDA approval of Otezla®.

Mark Awadalla's Education and Expertise

Mark Awadalla earned his Bachelor of Science in Biochemistry/Molecular Biology from the Richard Stockton University of New Jersey. His educational background laid the foundation for a career specializing in cell therapy clinical trials. Awadalla's expertise spans multiple therapeutic areas, including oncology, inflammation, degenerative, and rare diseases. His deep understanding of biochemistry and molecular biology has been crucial in his roles overseeing complex clinical operations.

Mark Awadalla's Achievements

Mark Awadalla has a track record of significant achievements in the biotech industry. At Celularity Inc., he oversaw a diverse clinical portfolio and successfully designed and executed several clinical trials. During his tenure at Mustang Bio, he led the team to clear INDs and start their first clinical trial involving an autologous cell therapy product. One of his notable contributions at Celgene was playing an integral role in the execution, management, and submission of global clinical trials, leading to the NDA approval of Otezla®, a major milestone in the treatment of psoriasis and psoriatic arthritis.